Infographic: A Guide to Briefs in the Amgen vs Sandoz Supreme Court Case

Article

Patent disputes have continued following the approval of filgrastim-sndz (Zarxio), a biosimilar product developed by Sandoz. Amgen, which markets the reference drug filgrastim (Neupogen), now claims that Sandoz did not provide sufficient information about the biosimilar, Zarxio. Here's a timeline of where the 2 companies stands today.

Related Videos
Ha Kung Wong, JD
GBW 2023 webinar
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Related Content
© 2024 MJH Life Sciences

All rights reserved.